Eagle Pharmaceuticals (EGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 64,646 | 66,305 | 60,699 | 65,901 | 74,136 |
| Cost of Goods | 16,858 | 17,300 | 19,866 | 23,651 | 23,664 |
| Gross Profit | 47,788 | 49,005 | 40,833 | 42,250 | 50,472 |
| Operating Expenses | 38,342 | 37,532 | 32,233 | 33,439 | 48,933 |
| Operating Income | 10,304 | 11,773 | 9,466 | 9,462 | 2,203 |
| Interest Expense | 1,448 | 1,516 | 1,980 | 1,147 | 552 |
| Other Income | 442 | -26 | 5,818 | -11,978 | -7,519 |
| Pre-tax Income | 9,298 | 10,231 | 13,304 | -3,663 | -5,868 |
| Income Tax | 4,134 | 4,481 | 5,139 | 3,468 | 3,582 |
| Net Income Continuous | 5,164 | 5,750 | 8,165 | -7,131 | -9,450 |
| Net Income | $5,164 | $5,750 | $8,165 | $-7,131 | $-9,450 |
| EPS Basic Total Ops | 0.39 | 0.44 | 0.57 | -0.54 | -0.74 |
| EPS Basic Continuous Ops | 0.39 | 0.44 | 0.57 | -0.54 | -0.74 |
| EPS Diluted Total Ops | 0.39 | 0.44 | 0.60 | -0.54 | -0.74 |
| EPS Diluted Continuous Ops | 0.39 | 0.44 | 0.59 | -0.54 | -0.74 |
| EPS Diluted Before Non-Recurring Items | 0.39 | 0.44 | 0.62 | -0.27 | -0.74 |
| EBITDA(a) | $16,733 | $17,446 | $16,454 | $13,432 | $3,955 |